Last updated: February 24, 2026
What is NDC 24689-0144?
NDC 24689-0144 refers to Cymbalta (Duloxetine), a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for major depressive disorder, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. It is marketed primarily by Eli Lilly.
Market Size and Demand Dynamics
Current Market Size
- The global antidepressant market was valued at approximately $14.8 billion in 2022.
- Duloxetine accounted for roughly 10% of this market, representing approximately $1.48 billion in global sales in 2022.
- The U.S. market comprises an estimated 70% of global sales, roughly $1 billion, with retail prescriptions exceeding 60 million annually.
Demand Drivers
- Growing prevalence of depression, anxiety, chronic pain conditions, and fibromyalgia.
- Increased diagnosis and awareness.
- Expansion of indications to off-label uses such as diabetic peripheral neuropathy.
Competitive Landscape
- Main competitors include sertraline, escitalopram, venlafaxine, and generics of duloxetine.
- Patent status: The original patent expired in 2017 in the U.S., leading to increased generic penetration.
Pricing Trends and Projections
Historical Price Trends
| Year |
Brand Name (Cymbalta) |
Average Wholesale Price (AWP) per 30-Tablet Pack |
Generic Duloxetine AWP per 30-Tablet Pack |
| 2015 |
$300 |
$285 |
| 2018 |
N/A (patent expired) |
$200 |
$130 |
| 2020 |
Low |
$160 |
$50 |
| 2022 |
Low |
$150 |
$50 |
Price Components
- Brand Cymbalta (pre-2017): Elevated prices due to patent exclusivity.
- Post-patent expiration: Significant price drop due to generics.
- Current generics: AWP averages around $50–$60 per 30-day supply.
Future Price Projections (Next 3-5 Years)
| Scenario |
Price Range (AWP per 30-Tablet Pack) |
Key Assumptions |
| Conservative |
$50–$70 |
Stable generics market with limited innovation or patent returns. |
| Moderate |
$40–$50 |
Increased generic competition, possible biosimilar entry for formulations. |
| Optimistic |
$30–$40 |
Further patent litigations or new formulations extending market exclusivity. |
Factors Influencing Price Movements
- Patent litigations and exclusivity extensions.
- Entry of biosimilars or new formulations (e.g., extended-release).
- PBM formulary policies favoring generics.
- Manufacturers' pricing strategies in response to competitor actions.
Market Risks and Opportunities
Risks
- Regulatory pressures to reduce drug prices.
- The rise of alternative therapies, including non-pharmacologic treatments.
- Healthcare policy shifts delaying drug approvals or expanding generics.
Opportunities
- Expansion into new markets or indications, bolstering sales.
- Development of combination therapies.
- Price optimization through formulary negotiations.
Regulatory and Policy Context
- As of 2023, duloxetine remains off-patent in the U.S.
- Price controls and reimbursement policies by CMS and private insurers influence retail prices.
- International markets may have different approval statuses and pricing benchmarks.
Key Takeaways
- Duloxetine (NDC 24689-0144) has transitioned from patent-protected brand to a predominantly generic market.
- Current pricing for generics averages around $50 per 30-day supply in the U.S.
- The market's future price trajectory hinges on competition, regulatory actions, and demand for new or extended formulations.
- The global antidepressant market continues to grow, driven by mental health awareness and expanding indications.
- Companies operating in this space must monitor patent disputes, reimbursement policies, and emerging therapies.
FAQs
Q1. What are the main factors affecting duloxetine's market share?
Patent expiration, generic competition, clinician and patient preference, and formulary policy.
Q2. How does the entry of biosimilars or new formulations impact price?
They can reduce prices through increased competition or extend market exclusivity if they offer clinically distinct options.
Q3. Are there upcoming regulatory changes expected to influence prices?
Potential policy shifts toward drug price transparency and negotiations could impact pricing but are uncertain.
Q4. How does the generic price compare to brand-name duloxetine?
Generic prices are approximately 50-80% lower than brand-name prices observed pre-2017.
Q5. Is there potential for growth in international markets?
Yes; emerging markets and regions with lower drug penetration could see growth, influenced by approval status and pricing policies.
References
- Statista. (2022). Global antidepressant market size and market share. https://www.statista.com
- IQVIA. (2022). Prescription drug market data. https://www.iqvia.com
- U.S. Food and Drug Administration. (2017). Patent status and patent expiry for duloxetine. https://www.fda.gov
- Bloomberg Intelligence. (2022). Generic drug pricing trends. https://www.bloomberg.com
- Centers for Medicare & Medicaid Services. (2023). Reimbursement policies. https://www.cms.gov
